Sharman JP, Egyed M, Jurczak W, Skarbnik A, et al. Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia. Leukemia 2024 Dec 3. doi: 10.1038/s41375-024-02487.
PMID: 39627506